Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Market Access Impact: Renal Cell Carcinoma (US) 2017

Product Code:
Publication Date:
April 2017

Who wins when high costs drag the leading brand down?

Market barriers affect nearly a quarter of renal cell carcinoma (RCC) prescriptions in the US. High costs especially are preventing oncologists we surveyed from prescribing some brands. Are they costing your brand market share, or are you winning share from more expensive competitors? Which other barriers are keeping doctors from prescribing your brand?

Get the answers in Market Access Impact: RCC (US).

Based on a survey of 100 medical oncologists, the report covers 10 major therapies from Amgen, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Novartis, Pfizer, and Roche. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.

Not your market? Click here to see the EU5 report

Request sample pages

Top Takeaways

  • Cost is dragging the leading brand down: It sees the biggest barrier-related share loss—mainly because it’s too expensive.
  • Some brands win when costs are high: The brand that sees the biggest net share gain owes nearly a third of it to other brands being too expensive.
  • Many doctors experience few barriers: 70 percent or more of surveyed doctors experience no more than one barrier with any of the surveyed brands.
  • Barriers affect nearly a quarter of prescriptions: Cost and market access barriers affect more prescriptions than all other barriers combined.
  • Hidden volatility: While the net effect is modest, many brands see significant share losses and gains. Win/loss breakdowns can help you spot—and exploit—competitors’ weaknesses.
  • Doctors are open to alternatives: most are willing to consider brands they don’t currently prescribe.

Insight into 10 Major RCC Drugs

  • Afinitor (everolimus; Novartis)
  • Avastin (bevacizumab; Roche)
  • Cabometyx (cabozantinib; Exelixis)
  • Inlyta (axitinib; Pfizer)
  • Lenvima (lenvatinib; Eisai/Novartis)
  • Nexavar (sorafenib; Bayer/Amgen)
  • Opdivo (nivolumab; Bristol-Myers Squibb)
  • Sutent (sunitinib; Pfizer)
  • Torisel (temsirolimus; Pfizer)
  • Votrient (pazopanib; Novartis)

Exploring Market Access Barriers

Market Access Impact: RCC (US) explores key issues affecting drug manufacturers. You’ll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don’t, but would consider it?
  • Why don’t doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 US-based medical oncologists, chosen from the largest community of validated physicians in the world.

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with RCC in total in the last month

We conducted the survey between April 3rd and 7th, 2017.


At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.


All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved